{"title":"案例研究。","authors":"B. Winchell","doi":"10.4135/9780857020024.n9","DOIUrl":null,"url":null,"abstract":"Publication Data featured in Molecular Cancer Therapeutics, Brack et al. 2014. Fynomer C12 Epitope Covagen developed COVA208, a bispecific FynomAb which targets two epitopes on HER2. This included a novel moiety, Fynomer C12, which was combined with a region of pertuzumab to create a bispecific that demonstrated superior activity to trastuzumab and pertuzumab in tumor models. Covagen required detailed epitope information for the novel moiety (Fynomer C12). This allowed them to better understand the molecule’s mechanism-of-action and to demonstrate its novelty.","PeriodicalId":76638,"journal":{"name":"The International journal of oral myology","volume":"2 2 1","pages":"47-51"},"PeriodicalIF":0.0000,"publicationDate":"1976-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Case study.\",\"authors\":\"B. Winchell\",\"doi\":\"10.4135/9780857020024.n9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Publication Data featured in Molecular Cancer Therapeutics, Brack et al. 2014. Fynomer C12 Epitope Covagen developed COVA208, a bispecific FynomAb which targets two epitopes on HER2. This included a novel moiety, Fynomer C12, which was combined with a region of pertuzumab to create a bispecific that demonstrated superior activity to trastuzumab and pertuzumab in tumor models. Covagen required detailed epitope information for the novel moiety (Fynomer C12). This allowed them to better understand the molecule’s mechanism-of-action and to demonstrate its novelty.\",\"PeriodicalId\":76638,\"journal\":{\"name\":\"The International journal of oral myology\",\"volume\":\"2 2 1\",\"pages\":\"47-51\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1976-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The International journal of oral myology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4135/9780857020024.n9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The International journal of oral myology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4135/9780857020024.n9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
发表于Molecular Cancer Therapeutics, Brack et al. 2014。Fynomer C12表位Covagen开发了COVA208，这是一种双特异性FynomAb，靶向HER2上的两个表位。这包括一个新的片段Fynomer C12，它与帕妥珠单抗的一个区域结合，形成一个双特异性，在肿瘤模型中表现出优于曲妥珠单抗和帕妥珠单抗的活性。Covagen需要新片段(Fynomer C12)的详细表位信息。这使他们能够更好地了解分子的作用机制，并展示其新颖性。
Publication Data featured in Molecular Cancer Therapeutics, Brack et al. 2014. Fynomer C12 Epitope Covagen developed COVA208, a bispecific FynomAb which targets two epitopes on HER2. This included a novel moiety, Fynomer C12, which was combined with a region of pertuzumab to create a bispecific that demonstrated superior activity to trastuzumab and pertuzumab in tumor models. Covagen required detailed epitope information for the novel moiety (Fynomer C12). This allowed them to better understand the molecule’s mechanism-of-action and to demonstrate its novelty.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
